ArticleCancer immunology, immunotherapy : CII2012

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.

Douglas G McNeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.